JP6996981B2 - マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法 - Google Patents

マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法 Download PDF

Info

Publication number
JP6996981B2
JP6996981B2 JP2017556794A JP2017556794A JP6996981B2 JP 6996981 B2 JP6996981 B2 JP 6996981B2 JP 2017556794 A JP2017556794 A JP 2017556794A JP 2017556794 A JP2017556794 A JP 2017556794A JP 6996981 B2 JP6996981 B2 JP 6996981B2
Authority
JP
Japan
Prior art keywords
antibody
seq
agent
sequence
isolated polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017556794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504925A5 (cg-RX-API-DMAC7.html
JP2018504925A (ja
Inventor
ジェイムズ ムーア スティーブン
ザイ ルー グエン マーガレット
アール．ホステッター ダニエル
バジルジェバ オルガ
ギャリー サガート ジェイソン
アレクサンダー テレット ジョナサン
ウィリアム ウェスト ジェイムズ
Original Assignee
シトムクス セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シトムクス セラピューティクス，インコーポレイティド filed Critical シトムクス セラピューティクス，インコーポレイティド
Publication of JP2018504925A publication Critical patent/JP2018504925A/ja
Publication of JP2018504925A5 publication Critical patent/JP2018504925A5/ja
Priority to JP2021204362A priority Critical patent/JP7540990B2/ja
Application granted granted Critical
Publication of JP6996981B2 publication Critical patent/JP6996981B2/ja
Priority to JP2024135724A priority patent/JP2024170436A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
JP2017556794A 2015-01-20 2016-01-20 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法 Active JP6996981B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021204362A JP7540990B2 (ja) 2015-01-20 2021-12-16 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法
JP2024135724A JP2024170436A (ja) 2015-01-20 2024-08-15 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562105490P 2015-01-20 2015-01-20
US62/105,490 2015-01-20
US201562258015P 2015-11-20 2015-11-20
US62/258,015 2015-11-20
US201662278713P 2016-01-14 2016-01-14
US62/278,713 2016-01-14
PCT/US2016/014132 WO2016118629A1 (en) 2015-01-20 2016-01-20 Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021204362A Division JP7540990B2 (ja) 2015-01-20 2021-12-16 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2018504925A JP2018504925A (ja) 2018-02-22
JP2018504925A5 JP2018504925A5 (cg-RX-API-DMAC7.html) 2019-02-28
JP6996981B2 true JP6996981B2 (ja) 2022-03-03

Family

ID=55358121

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017556794A Active JP6996981B2 (ja) 2015-01-20 2016-01-20 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法
JP2021204362A Active JP7540990B2 (ja) 2015-01-20 2021-12-16 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法
JP2024135724A Pending JP2024170436A (ja) 2015-01-20 2024-08-15 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021204362A Active JP7540990B2 (ja) 2015-01-20 2021-12-16 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法
JP2024135724A Pending JP2024170436A (ja) 2015-01-20 2024-08-15 マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法

Country Status (20)

Country Link
US (5) US11046759B2 (cg-RX-API-DMAC7.html)
EP (2) EP4079323A1 (cg-RX-API-DMAC7.html)
JP (3) JP6996981B2 (cg-RX-API-DMAC7.html)
KR (1) KR102784383B1 (cg-RX-API-DMAC7.html)
CN (7) CN114685661B (cg-RX-API-DMAC7.html)
AU (2) AU2016209403A1 (cg-RX-API-DMAC7.html)
CA (1) CA2974087A1 (cg-RX-API-DMAC7.html)
DK (1) DK3247393T3 (cg-RX-API-DMAC7.html)
EA (1) EA201791647A1 (cg-RX-API-DMAC7.html)
ES (1) ES2919879T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220631T8 (cg-RX-API-DMAC7.html)
HU (1) HUE058974T2 (cg-RX-API-DMAC7.html)
IL (2) IL253599B2 (cg-RX-API-DMAC7.html)
MA (1) MA41374A (cg-RX-API-DMAC7.html)
PL (1) PL3247393T3 (cg-RX-API-DMAC7.html)
PT (1) PT3247393T (cg-RX-API-DMAC7.html)
RS (1) RS63276B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201913901QA (cg-RX-API-DMAC7.html)
WO (1) WO2016118629A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208160B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024170436A (ja) * 2015-01-20 2024-12-10 シトムクス セラピューティクス，インコーポレイティド マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673267B2 (en) 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
CA2915412A1 (en) * 2012-06-14 2013-12-19 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
EP4067383A1 (en) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL302642B2 (en) 2014-01-31 2025-04-01 Cytomx Therapeutics Inc Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
JP6841754B2 (ja) 2015-05-13 2021-03-10 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
AU2017355446A1 (en) 2016-11-03 2019-05-02 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
MX2019005947A (es) 2016-11-28 2019-08-26 Chugai Pharmaceutical Co Ltd Molecula de union a ligando que tiene actividad de union a ligando ajustable.
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
CA3042276A1 (en) 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
AU2017388894A1 (en) * 2016-12-29 2019-08-08 Development Center For Biotechnology KLK6-mediated CNS-specific antibody prodrug activation
US11519905B2 (en) 2017-04-07 2022-12-06 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
BR112019020940A2 (pt) 2017-04-11 2020-05-05 Inhibrx, Inc. construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas
EP3655779A1 (en) * 2017-07-20 2020-05-27 CytomX Therapeutics, Inc. Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
CN111278461A (zh) 2017-08-16 2020-06-12 百时美施贵宝公司 可前药化抗体、其前药以及使用和制备方法
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
EP3762420A1 (en) * 2018-03-09 2021-01-13 CytomX Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
EP3788077A1 (en) 2018-05-02 2021-03-10 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
ES2955511T3 (es) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
IL278615B1 (en) 2018-05-14 2025-10-01 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of using them
WO2019230867A1 (en) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
US20210253672A1 (en) 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3114693A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
AU2019394972A1 (en) * 2018-12-06 2021-06-03 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
AU2020240310A1 (en) 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
EP3958977B1 (en) 2019-04-26 2023-09-13 ImmunoGen, Inc. Camptothecin derivatives
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
CN114423499A (zh) * 2019-06-06 2022-04-29 佳努克斯治疗公司 与肿瘤激活的t细胞衔接子相关的组合物和方法
WO2020251878A1 (en) 2019-06-11 2020-12-17 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
US20220281936A1 (en) * 2019-07-25 2022-09-08 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
KR102386849B1 (ko) 2019-10-14 2022-04-13 포항공과대학교 산학협력단 면역치료를 위한 환경 반응형 접착성 항체전달체 및 이의 제조방법
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR20220148175A (ko) 2020-01-29 2022-11-04 인히브릭스, 인크. Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
WO2021189139A1 (en) * 2020-03-23 2021-09-30 Blackler Ryan Masked il12 fusion proteins and methods of use thereof
EP4132656A1 (en) 2020-04-09 2023-02-15 CytomX Therapeutics, Inc. Compositions containing activatable antibodies
US11365233B2 (en) 2020-04-10 2022-06-21 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN116348597A (zh) 2020-08-11 2023-06-27 佳努克斯治疗公司 可切割性接头组合物和方法
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ， インコーポレイテッド 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
IL303270A (en) 2020-12-21 2023-07-01 Allogene Therapeutics Inc The CD45–GATE vehicle activates a protease
MX2023010840A (es) 2021-03-16 2023-10-26 Cytomx Therapeutics Inc Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.
WO2023034825A1 (en) 2021-08-30 2023-03-09 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
AU2022361492A1 (en) 2021-10-08 2024-05-02 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
JP2024538706A (ja) 2021-10-08 2024-10-23 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構成体及び併用方法
TW202323282A (zh) 2021-10-15 2023-06-16 美商賽特艾克斯生物製藥公司 可活化之多肽複合物
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
MX2024004563A (es) * 2021-10-15 2024-04-30 Cytomx Therapeutics Inc Complejo polipeptidico activable.
CN119072488A (zh) 2022-02-23 2024-12-03 明峰治疗股份公司 可活化il-18多肽
US20250197917A1 (en) * 2022-03-09 2025-06-19 Glympse Bio, Inc. Method of protease detection
US20250196099A1 (en) 2022-03-23 2025-06-19 Sony Group Corporation Structure
US20250333539A1 (en) 2022-03-23 2025-10-30 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
EP4499685A1 (en) 2022-03-25 2025-02-05 CytomX Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
CN119278215A (zh) 2022-04-01 2025-01-07 西托姆克斯治疗公司 Cd3结合蛋白和其使用方法
CN119300859A (zh) 2022-04-01 2025-01-10 西托姆克斯治疗公司 可激活多特异性分子和其使用方法
US20250136717A1 (en) 2022-05-16 2025-05-01 Byondis B.V. Novel masked antibodies
TW202426637A (zh) 2022-08-01 2024-07-01 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割受質及其使用方法
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
TW202424184A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割部分及其使用方法
AR130079A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
US20250197467A1 (en) 2023-08-23 2025-06-19 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014107599A2 (en) 2013-01-04 2014-07-10 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
JP2015193654A (ja) 2009-01-12 2015-11-05 サイトムエックス セラピューティクス, インク.Cyto 改変した抗体組成物、それを作製および使用する方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
AR007087A1 (es) 1996-05-10 1999-10-13 Danisco Una codificacion de fragmento de adn aislado para una enzima que posee actividad de alfa-glucuronidasa, fragmento de adn correspondiente, vectorrecombinante que tiene insertada dicha codificacion de fragmento de adn, celula huesped transformada con dicho vector recombinante, metodo para producir alfa-
AUPO930697A0 (en) 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU762814B2 (en) 1998-05-13 2003-07-03 Domantis Limited Selection system
WO2001055173A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
AU2001280464A1 (en) 2000-08-04 2002-02-18 Eli Lilly And Company C1q-related factor, homologous polypeptides and therapeutic uses thereof
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU2002230630A1 (en) 2000-11-08 2002-05-21 Beth Israel Deaconess Medical Center, Inc. Methods for determining protease cleavage site motifs
JP2005506047A (ja) * 2001-03-27 2005-03-03 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー 膜貫通型セリンプロテアーゼ９をコード化する核酸分子、コード化されたポリペプチドおよびそれらに基づく方法
AU2002315525A1 (en) * 2001-07-03 2003-01-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
US7439319B2 (en) 2001-09-14 2008-10-21 Burnham Institute For Medical Research Selective substrates for matrix metalloproteinases
WO2003038083A1 (en) 2001-10-29 2003-05-08 Bayer Healthcare Ag Regulation of human type i adenylate cyclase
WO2003068934A2 (en) 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
WO2004099254A2 (en) * 2003-05-06 2004-11-18 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Activation of recombinant diphtheria toxin fusion proteins by specific proteases highly expressed on the surface of tumor cells
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US9079936B2 (en) 2003-07-01 2015-07-14 University Of Maryland, Baltimore Derivatives of APF and methods of use
WO2005090393A2 (en) * 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007105027A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
RU2483080C2 (ru) 2006-10-27 2013-05-27 Дженентек, Инк. Антитела и иммуноконъюгаты и их применение
TWI412367B (zh) * 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
WO2010088691A2 (en) 2009-02-02 2010-08-05 Washington State University Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
JP5843357B2 (ja) * 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
WO2011028698A2 (en) 2009-09-02 2011-03-10 Kansas State University Research Foundation Mri and optical assays for proteases
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
CA2799969C (en) 2010-05-20 2019-06-25 Allergan, Inc. Degradable clostridial toxins
GB201009271D0 (en) 2010-06-02 2010-07-21 Promar As Compositions
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
MX340556B (es) * 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
CN103732256A (zh) 2011-05-16 2014-04-16 皇家飞利浦有限公司 生物正交药物活化
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
RU2639526C2 (ru) 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
US20130078201A1 (en) 2011-09-28 2013-03-28 Susan Daly Topical sunscreen compositions
AU2013251310B2 (en) 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
KR20150037857A (ko) 2012-06-22 2015-04-08 싸이톰스 테라퓨틱스, 인크. 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
HK1222122A1 (zh) 2013-04-22 2017-06-23 Avelas Biosciences, Inc. 选择性药物递送组合物及使用方法
KR20160018579A (ko) * 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL302642B2 (en) 2014-01-31 2025-04-01 Cytomx Therapeutics Inc Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof
AU2015292406B2 (en) * 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
ES2796698T3 (es) * 2015-05-04 2020-11-30 Cytomx Therapeutics Inc Anticuerpos anti-CD166 activables y procedimientos de uso de los mismos
CN107922490A (zh) 2015-05-04 2018-04-17 西托姆克斯治疗公司 抗ITGa3抗体、可活化抗ITGa3抗体及其使用方法
US10179817B2 (en) * 2015-05-04 2019-01-15 Cytomx Therapeutics, Inc. Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
JP2018518972A (ja) 2015-06-26 2018-07-19 ユニバーシティ オブ サザン カリフォルニア 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
AU2017355446A1 (en) 2016-11-03 2019-05-02 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP3864407A4 (en) 2018-10-11 2022-07-13 Northwestern University BIOMARKERS OF CHRONIC KIDNEY DISEASE IN LIVER TRANSPLANT RECIPIENTS
AU2019394972A1 (en) 2018-12-06 2021-06-03 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015193654A (ja) 2009-01-12 2015-11-05 サイトムエックス セラピューティクス, インク.Cyto 改変した抗体組成物、それを作製および使用する方法
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014107599A2 (en) 2013-01-04 2014-07-10 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY, IMMUNOTHERAPY，ドイツ，2006年04月25日，VOL:55, NR:12，PAGE(S):1590 - 1600，http://dx.doi.org/10.1007/s00262-006-0162-6

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024170436A (ja) * 2015-01-20 2024-12-10 シトムクス セラピューティクス，インコーポレイティド マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法

Also Published As

Publication number Publication date
CN114685611B (zh) 2025-01-07
US20220380453A9 (en) 2022-12-01
NZ772090A (en) 2024-07-05
HK1247131A1 (en) 2018-09-21
IL253599B1 (en) 2023-03-01
US11472875B1 (en) 2022-10-18
AU2021257963B2 (en) 2025-02-27
JP2024170436A (ja) 2024-12-10
KR20170108052A (ko) 2017-09-26
AU2016209403A1 (en) 2017-08-03
CN114907446A (zh) 2022-08-16
CN114685611A (zh) 2022-07-01
US20230021301A9 (en) 2023-01-19
HRP20220631T1 (hr) 2022-06-24
NZ733811A (en) 2024-07-05
CN114907446B (zh) 2024-08-02
JP7540990B2 (ja) 2024-08-27
US11548944B2 (en) 2023-01-10
CN107531758B (zh) 2022-02-11
CN107531758A (zh) 2018-01-02
BR112017015468A2 (pt) 2018-06-05
US20190241652A9 (en) 2019-08-08
EP3247393A1 (en) 2017-11-29
IL300408B1 (en) 2025-07-01
DK3247393T3 (da) 2022-05-23
PT3247393T (pt) 2022-07-01
CN114478704A (zh) 2022-05-13
ZA202208160B (en) 2024-11-27
US11046759B2 (en) 2021-06-29
HUE058974T2 (hu) 2022-10-28
US20160289324A1 (en) 2016-10-06
PL3247393T3 (pl) 2022-06-27
EA201791647A1 (ru) 2018-04-30
IL253599A0 (en) 2017-09-28
IL300408B2 (en) 2025-11-01
CN114685661A (zh) 2022-07-01
CN119119209A (zh) 2024-12-13
NZ772087A (en) 2024-07-05
US11548943B2 (en) 2023-01-10
EP4079323A1 (en) 2022-10-26
IL253599B2 (en) 2023-07-01
HRP20220631T8 (hr) 2022-07-08
CN114685661B (zh) 2025-01-07
JP2018504925A (ja) 2018-02-22
US20210347886A1 (en) 2021-11-11
US20210355208A1 (en) 2021-11-18
JP2022046569A (ja) 2022-03-23
CA2974087A1 (en) 2016-07-28
CN114478704B (zh) 2024-07-26
CN114716513A (zh) 2022-07-08
EP3247393B1 (en) 2022-03-09
SG10201913901QA (en) 2020-03-30
AU2021257963A1 (en) 2021-11-25
RS63276B1 (sr) 2022-06-30
SG11201705901PA (en) 2017-08-30
NZ772089A (en) 2024-07-05
US12459999B2 (en) 2025-11-04
US20230212283A1 (en) 2023-07-06
IL300408A (en) 2023-04-01
KR102784383B1 (ko) 2025-03-24
WO2016118629A1 (en) 2016-07-28
MA41374A (fr) 2017-11-28
ES2919879T3 (es) 2022-07-28

Similar Documents

Publication Publication Date Title
JP7540990B2 (ja) マトリックスメタロプロテアーゼ切断可能及びセリンプロテアーゼ切断可能な基質並びにそれらの使用方法
JP7781254B2 (ja) マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
JP6915987B2 (ja) マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
JP6835586B2 (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
TWI902404B (zh) 基質金屬蛋白酶可切割且絲胺酸蛋白酶或半胱胺酸蛋白酶可切割之受質和彼之使用方法
EA042544B1 (ru) Расщепляемые матриксными металлопротеиназами и расщепляемые сериновыми протеиназами вещества и способы их использования
BR112017015468B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo-os, uso terapêutico destes, molécula de ácido nucleico isolada, vetor, método para produzir um polipeptídeo isolado e método para fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211216

R150 Certificate of patent or registration of utility model

Ref document number: 6996981

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250